文献速递皮肤感染

眼镜蛇毒注射液对比普瑞巴林治疗中重度急性带状疱疹神经痛的随机双盲双模拟多中心探索性试验

Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial.
PubMed 文献 · J Am Acad Dermatol · 2026-06-19

这项多中心随机双盲双模拟活性对照探索性试验纳入80例50-70岁中重度急性带状疱疹神经痛患者,1:1接受眼镜蛇毒注射液肌注或口服普瑞巴林28天。第28天NRS疼痛评分最小二乘均值下降分别为6.00和5.63(组间差0.37,P=.186);第12周PHN发生率分别为0/27和3/27(P=.236);治疗中出现不良事件分别为35.9%和51.2%。结论为两者镇痛幅度相近,眼镜蛇毒注射液耐受性信号较好,需更大样本确证。

要点

  • 眼镜蛇毒注射液与普瑞巴林第28天NRS下降相近(6.00 vs 5.63,P=.186)
  • 第12周PHN发生率两组分别0/27与3/27(P=.236),差异未达统计学显著
  • 不良事件发生率眼镜蛇毒注射液组35.9%,低于普瑞巴林组51.2%

核心结论

  • 眼镜蛇毒注射液治疗中重度急性带状疱疹神经痛的镇痛幅度与普瑞巴林相近,且耐受性信号较好。
  • 第12周PHN发生率两组差异无统计学意义,需更大样本研究确认其对PHN的潜在影响。

研究设计与样本

  • 多中心、随机、双盲、双模拟、活性对照探索性试验,80例50-70岁中重度急性带状疱疹神经痛患者按1:1分组。
  • 眼镜蛇毒注射液肌内注射或口服普瑞巴林治疗28天,主要终点为基线至第28天平均NRS疼痛评分变化。
  • 未进行正式把握度计算。

主要发现

  • 第28天NRS疼痛评分最小二乘均值下降:眼镜蛇毒注射液组6.00,普瑞巴林组5.63,组间差0.37(P=.186)。
  • 第12周PHN发生:眼镜蛇毒注射液组0/27例,普瑞巴林组3/27例(P=.236)。
  • 治疗中出现的不良事件发生率:眼镜蛇毒注射液组35.9%,普瑞巴林组51.2%。

临床怎么用

  • 对于50-70岁中重度急性带状疱疹神经痛患者,眼镜蛇毒注射液可作为与普瑞巴林镇痛幅度相近的候选方案,但需结合耐受性个体化选择。
  • 因证据来自探索性小样本试验,暂不宜据此改变常规一线镇痛策略,应等待更大规模确证性研究。

局限性

  • 探索性设计且样本量小,统计推断能力有限。
  • 未系统收集带状疱疹疫苗接种史及皮疹出现时间,限制推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute herpes zoster (HZ) neuralgia impairs quality of life and may progress to postherpetic neuralgia (PHN). Existing analgesics are often limited by adverse effects in older adults. OBJECTIVE: To evaluate Cobratide injection for moderate-to-severe acute HZ neuralgia and explore its potential effect on PHN incidence. METHODS: In this multicenter, randomized, double-blind, double-dummy, active-controlled exploratory trial, 80 patients aged 50-70 years were assigned 1:1 to intramuscular Cobratide injection or oral Pregabalin for 28 days. The primary endpoint was change in average Numeric Rating Scale (NRS) pain score from baseline to day 28. No formal power calculation was performed. RESULTS: At day 28, least-squares mean NRS reductions were 6.00 with Cobratide injection and 5.63 with Pregabalin (between-group difference, 0.37; P = .186). At week 12, PHN occurred in 0/27 and 3/27 evaluable patients, respectively (P = .236). Treatment-emergent adverse events occurred in 35.9% and 51.2% of patients, respectively. LIMITATIONS: Exploratory design, small sample size, and lack of systematic collection of zoster vaccination history and rash-onset timing limited inference. CONCLUSIONS: Cobratide injection showed a similar magnitude of pain reduction to Pregabalin, with a favorable tolerability signal. Larger adequately powered trials are needed.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Xu X, Han X, Li X, et al. Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial. J Am Acad Dermatol. 2026. PMID: 42320855. doi:10.1016/j.jaad.2026.06.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。